Gefitinib Treatment in EGFR Mutated Caucasian NSCLC: Circulating-Free Tumor DNA as a Surrogate for Determination of EGFR Status

INTRODUCTION: In the phase IV, open-label, single-arm study NCT01203917, first-line gefitinib 250 mg/d was effective and well tolerated in Caucasian patients with epidermal growth factor receptor (EGFR) mutation-positive non–small-cell lung cancer (previously published). Here, we report EGFR mutatio...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Thorac Oncol
Main Authors: Douillard, Jean-Yves, Ostoros, Gyula, Cobo, Manuel, Ciuleanu, Tudor, Cole, Rebecca, McWalter, Gael, Walker, Jill, Dearden, Simon, Webster, Alan, Milenkova, Tsveta, McCormack, Rose
Formato: Artigo
Idioma:Inglês
Publicado em: Lippincott Williams & Wilkins 2014
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4224589/
https://ncbi.nlm.nih.gov/pubmed/25122430
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/JTO.0000000000000263
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados